J.P. Stevenson
University of Pennsylvania Cancer Center
Philadelphia
USA
Name/email consistency: high
- Irinotecan and UFT/leucovorin in patients with advanced cancers. Stevenson, J.P., Redlinger, M., Sun, W., Haller, D., O'Dwyer, P.J. Oncology (Williston Park, N.Y.) (2000)
- Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. Stevenson, J.P., DeMaria, D., Sludden, J., Kaye, S.B., Paz-Ares, L., Grochow, L.B., McDonald, A., Selinger, K., Wissel, P., O'Dwyer, P.J., Twelves, C. Ann. Oncol. (1999)
- Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule. Stevenson, J.P., DeMaria, D., Reilly, D., Purvis, J.D., Graham, M.A., Lockwood, G., Drozd, M., O'Dwyer, P.J. Cancer Chemother. Pharmacol. (1999)